HUTCHMED Limited announces that the Center for Drug Evaluation of China’s National Medical Products Administration has granted Breakthrough Therapy Designation to the combination of fruquintinib and sintilimab for the treatment of patients with advanced endometrial cancer with pMMR1 tumors that have failed at least one line of platinum-based therapy.
